Alembic Pharmaceuticals Limited has informed the Exchange about change in Management
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts more than Nifty Microcap 250 and 2.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Pharmaceuticals has informed the exchanges that Mr. Viraj Save, Executive Vice President – Sales and Marketing (heading the CV/Cardiovascular cluster), has resigned from the company. He sent his resignation email on 2nd May 2025 serving a three-month notice period, with an implied relieving date of 31st July 2025, but was actually relieved earlier on 31st May 2025. The company disclosed this to the exchanges only on 25th June 2025, acknowledging a delay in reporting and stating that such inadvertent delays will not be repeated. The disclosure is filed under SEBI Listing Regulations read with the November 2024 SEBI Master Circular.
The exit of a senior executive overseeing the Cardiovascular sales vertical may create short-term uncertainty around continuity in an important therapeutic segment, though the company has not flagged any business disruption. The admitted delay in informing the exchanges is a minor governance red flag that investors may want to track going forward.